QIAGEN GmbH
QIAGEN Strasse 1
40724 Hilden
Germany

December 2020

Dear valued customer,

QIAGEN is dedicated to meeting the needs of our customers, and we continually strive to provide the best value in products and services. During this time of the COVID-19 pandemic, new information on the SARS-CoV-2 virus is developing rapidly. This includes the recent outbreak of the SARS-CoV-2 VUI – 202012/01 variant. It was discovered in England, and currently, there are greater than 1000 cases in the South and East of England.

QIAGEN keeps continuous surveillance on SARS-CoV-2 genetic variation to identify any potential mutation on the SARS-CoV-2 genome. In particular, how mutations could affect the sensitivity of the QIAGEN assays currently used in the fight against COVID-19 such as the QIAstat-Dx Respiratory SARS-CoV-2 Panel, NeuMoDx SARS-CoV-2 Assay and NeuMoDx Flu A-B/RSV/SARS-CoV-2 Assay.

Our Medical Affairs team indicates that the recorded genetic variability of the SARS-CoV-2 VUI – 202012/01 variant affecting the South and East of England does not affect the genomic regions targeted by RT-PCR assays in the QIAstat-Dx Respiratory SARS-CoV-2 Panel, NeuMoDx SARS-CoV-2 Assay and NeuMoDx Flu A-B/RSV/SARS-CoV-2 Assay. The SARS-CoV-2 VUI-202012/01 mutation impacts the S gene of the SARS-CoV-2 genome, and all of the QIAGEN SARS-CoV-2 tests do not target the S gene for the detection of the virus.

From the onset of the novel coronavirus outbreak, QIAGEN's dedicated global teams have been working around the clock to support the worldwide fight against COVID-19. To support our customers, we will continue with our genetic variation surveillance and keep you updated. Please do not hesitate to reach out to your local QIAstat-Dx and NeuMoDx specialist if you have any further questions.

Best regards,

Davide Manissero, MD
Chief Medical Officer

Sajid Javed
Infectious diseases Senior Global Product Manager